Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 165 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
3.Enlace a cita original Cita con resumen
Mullard A. Flooded by the torrent: the COVID-19 drug pipeline. Lancet 2020;395:8 de abril. [Ref.ID 103591]
4. Cita con resumen
DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:1 de febrero. [Ref.ID 103519]
5.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
6.Enlace a cita original Cita con resumen
Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
McCormack J, Korownyk C. Effectiveness of antidepressants. BMJ 2018;360:k1073. [Ref.ID 102478]
8. Cita con resumen
9. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
10. Cita con resumen
Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]
11.Tiene citas relacionadas Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
14. Cita con resumen
Dalsgaard S, Ostergaard D, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 2015;385:2190-6. [Ref.ID 99164]
15. Cita con resumen
Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031-9. [Ref.ID 98939]
16.Tiene citas relacionadas Cita con resumen
McPherson K. NICE on statins. Concerns about the latest NICE draft guidance on statins. BMJ 2014;349:g4192. [Ref.ID 98134]
17.Tiene citas relacionadas Cita con resumen
Steinbrook R. Should medical journal publish sponsored content?. BMJ 2014;348:g352. [Ref.ID 97341]
18.Tiene citas relacionadas Cita con resumen
Wedzicha JA. Should medical journals publish sponsored content? Yes. BMJ 2014;348:g352. [Ref.ID 97340]
19. Cita con resumen
Cohen D. FDA official: "clinical trial system is broken". BMJ 2013;347:f6980. [Ref.ID 97177]
20. Cita con resumen
Drazen JM. Open data. N Engl J Med 2014;370:662. [Ref.ID 97117]
Seleccionar todas
 
 1 a 20 de 165 siguiente >>